CoreLine Soft Co Ltd

The company's capital structure is characterized by a high proportion of equity, with total equity of KRW 10,612,635,480 and total liabilities of KRW 2,854,083,540, resulting in a debt-to-equity ratio of 0.06. The liquidity position is mixed, with a current ratio of 5.26, indicating strong short-term liquidity, but negative operating and free cash flows of KRW -3,092,245,760 and KRW -2,932,889,890, respectively, signaling cash flow challenges. The price-to-book ratio of 5.95 suggests the market is valuing the company significantly above its book value, despite negative returns on equity and assets of -28.83% and -22.72%, respectively.

Profitability metrics are severely underperforming relative to industry norms. The company reported a net loss of KRW -3,059,361,100 and an operating loss of KRW -3,407,446,990, with a gross profit of KRW 600,499,220 on revenue of KRW 712,669,220. These figures indicate a significant decline in operational efficiency and profitability, with a negative return on equity and assets, which are far below the typical performance of firms in the Advanced Medical Equipment & Technology industry.

Geographic and segment exposure is not explicitly detailed in the available data, but the company's revenue concentration is likely within the healthcare equipment segment. The absence of disclosed geographic breakdowns or segment-specific financials limits the ability to assess diversification risk. However, the company's primary activity is in healthcare equipment, which is a key driver of its revenue.

The growth trajectory is currently negative, with a net loss and declining cash flows. The company's revenue of KRW 712,669,220 is insufficient to cover operating expenses, and the negative operating cash flow of KRW -3,092,245,760 suggests a reliance on external financing or asset sales to sustain operations. The outlook for the current fiscal year is uncertain, with no clear indication of a turnaround in profitability or cash flow generation.

Risk factors include liquidity constraints and the potential for dilution. The company has a low dilution risk, but the negative net cash position after subtracting total debt raises concerns about its ability to meet short-term obligations. The risk assessment highlights the need for improved cash flow management and operational efficiency to mitigate liquidity risks.

Recent events, such as filings and transcripts, are not provided in the available data, so no specific recent developments can be cited. However, the company's financial performance and risk profile suggest a need for strategic adjustments to address its current challenges.

Revenue grew 9.0% year-over-year to 4.28 billion KRW, indicating top-line expansion despite ongoing profitability challenges.

Operating losses narrowed by 2.4% year-over-year, suggesting a slight improvement in core operational efficiency compared to the prior period.

Cash conversion ratio of 1.01 exceeds the cohort median of 0.79, indicating relatively strong cash generation relative to earnings.

Debt-to-equity ratio of 0.06 matches the cohort median, reflecting a conservative leverage position within the advanced medical equipment sector.

Dilution risk is assessed as low, providing some protection to existing shareholders against immediate equity value erosion.

The company posted a net loss of 14.5 billion KRW, resulting in a negative net margin of -4.29%.

Operating and net margins rank in the bottom quartile of the 196-company advanced medical equipment cohort.

Credit risk is flagged as high, posing significant concerns regarding the company's ability to meet its financial obligations.